Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 1.27% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 4.11% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 12.75% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for KYMR reached as high as $2.1 million in Q3 2025 and fell as low as $687000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.4 million across 5 years, with a median of $1.5 million in 2024.
• Across the five-year window, Depreciation & Amortization (CF) jumped 123.01% in 2024 and declined 1.27% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $818000.0 in 2022, then increased by 8.92% to $891000.0 in 2023, then soared by 123.01% to $2.0 million in 2024, then gained by 2.26% to $2.0 million in 2025, then fell by 0.49% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.